Platelet membrane-coated nanoparticles carrying Defactinib and PD-L1 antibodies reduced tumor matrix rigidity and improved immune cell infiltration in preclinical CRC models, suggesting a strategy to overcome checkpoint inhibitor resistance. (Journal of Nanobiotechnology)
CRC Research Finding
The CRC Digest